New delivery systems may revive potential of peptide drugs

01/14/2005 |

New therapeutic approaches, plus the potential of the drugs themselves, may mean a renaissance in peptide drugs, according to a new report. Approval of new peptide-based drug products, such as Roche's HIV treatment Fuzeon, is increasing interest among pharmaceutical companies. In Europe, as many as six peptide-based products are on the market, with 100 in the clinical stage and 150 in advanced preclinical phases.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA